ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous Tumor Infiltrating Lymphocytes GT201

Also written as “GT201”, “Autologous tumor infiltrating lymphocyte injection(GT201)” and “GT201 injection”.

Its studies are mostly in Lung Neoplasms · Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.

Drug pageAutologous Tumor Infiltrating Lymphocytes GT201: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Feb 6, 20239 company-led studies, 3 open or runningNext primary completion: Apr 30, 2027

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Grit Biotechnology82 open or runningphase 2since Feb 6, 2023Jun 4, 2022Apr 30, 2027NCT06190275
Gritbio Medicineits history only11 open or runningphase 2since Jul 27, 2026Jul 27, 2026Jun 2030phase 2 · NCT07766317

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Grit Biotechnology only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 4, 2022First study: phase 1 study in Solid TumorFirst studyNCT05430360 · 2 enrolled · China
  2. Feb 6, 2023Phase 2 study in Solid TumorNCT05729399 · 6 enrolled · China
  3. Oct 20, 2023Phase 2 study in Advanced Solid TumorsNCT06144671 · 78 planned · China
  4. Dec 19, 20232 no phase studiesNCT06190275, NCT06191900
  5. Jan 23, 2024No phase study in Carcinoma, Non-Small-Cell LungNCT06235242 · 2 enrolled · China
  6. Jul 19, 2024No phase study in Lung NeoplasmsNCT06519669 · 2 enrolled · China
  7. Feb 5, 2025Early phase 1 study in Adult Gynecological TumorsNCT06834542 · 1 enrolled · China

Ahead

  1. Apr 30, 2027Primary completion: no phase study in Squamous Cell Carcinoma of Head and NeckNCT06190275
  2. Dec 30, 2027Primary completion: phase 2 study in Advanced Solid TumorsNCT06144671

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 Grit Biotechnology leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06834542Adult Gynecological Tumors · ChinaEarly 1TerminatedDec 30, 20251
NCT06519669Lung Neoplasms · China–TerminatedDec 30, 20252
NCT06235242Carcinoma, Non-Small-Cell Lung · China–TerminatedDec 30, 20252
NCT06191900Adult · China–TerminatedDec 30, 20254
NCT06190275Squamous Cell Carcinoma of Head and Neck · China–RecruitingApr 30, 202732
NCT06144671Advanced Solid Tumors · China2RecruitingDec 30, 202778
NCT05729399Solid Tumor · China2TerminatedDec 30, 20256
NCT05430360Solid Tumor · China1TerminatedDec 30, 20252

How it is read

Names in the registry

  • “GT201”, 4 entries
  • “Autologous tumor infiltrating lymphocyte injection(GT201)”, 2 entries
  • “GT201 injection”, 1 entry
  • “GT201 injection in combination with teraplizumab injection”, 1 entry
  • “GT201 in combination with PD-1 inhibitors”, 1 entry

Codes read as this program: GT201.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.